What is the initial dosage of epinephrine (adrenaline) for refractory shock?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Initial Epinephrine Dosage for Refractory Shock

For refractory shock, the initial epinephrine dosage should be 0.1 mcg/kg/min intravenously, titrated to desired clinical effect with a range of 0.1-1.0 mcg/kg/min. 1

Pharmacological Considerations

Epinephrine is a potent vasopressor with both alpha and beta adrenergic effects that can be life-saving in refractory shock when first-line agents have failed. When administering epinephrine:

  • Start at the lowest effective dose (0.1 mcg/kg/min) to minimize adverse effects 1
  • Titrate carefully in increments of 0.05-0.2 mcg/kg/min every 10-15 minutes 2
  • Maximum doses as high as 5 mcg/kg/min may occasionally be necessary in severe cases 1
  • FDA-approved dosing range for septic shock is 0.05-2 mcg/kg/min 3

Administration Guidelines

Preparation and Delivery

  • Dilute 1 mg (1 mL) of epinephrine in 100 mL of normal saline to create a 10 mcg/mL solution 2
  • Administer through a central venous line whenever possible to reduce risk of extravasation 1
  • If central access is unavailable, peripheral administration can be used temporarily while obtaining central access 2
  • Avoid using veins of the leg in elderly patients or those with occlusive vascular diseases 3

Monitoring Requirements

  • Continuous cardiac monitoring is essential
  • Frequent blood pressure measurements (every minute if continuous monitoring unavailable)
  • Regular assessment of tissue perfusion (capillary refill, urine output, mental status)
  • Monitor for signs of digital ischemia due to peripheral vasoconstriction 2

Clinical Considerations

When to Use Epinephrine for Refractory Shock

  • After failure of initial fluid resuscitation
  • When first-line vasopressors (typically norepinephrine) have failed to restore adequate perfusion
  • As a second-line agent in septic shock 1
  • As a first-line agent in cardiogenic shock with low cardiac output 1

Potential Adverse Effects

  • Tachyarrhythmias and ectopic beats
  • Increased myocardial oxygen consumption
  • Lactic acidosis (independent of tissue perfusion due to metabolic effects) 1
  • Hyperglycemia due to inhibition of insulin and stimulation of gluconeogenesis 1
  • Tissue necrosis if extravasation occurs 1

Special Situations

Extravasation Management

  • If extravasation occurs, immediately infiltrate the area with phentolamine (0.1-0.2 mg/kg up to 10 mg diluted in 10 mL of 0.9% sodium chloride) 1
  • This counteracts dermal vasoconstriction and may prevent tissue necrosis

Beta-Blocker Overdose

  • Higher doses of epinephrine may be considered in beta-blocker overdose (Class IIb, LOE C) 1
  • IV glucagon (1-2 mg) may also be required in these cases 2

Weaning Considerations

  • After hemodynamic stabilization, wean incrementally over time
  • Consider decreasing doses every 30 minutes over a 12-24 hour period 3
  • Monitor closely for recurrence of hypotension during weaning

Cautions and Contraindications

  • Use with caution in patients with coronary artery disease due to increased myocardial oxygen demand 2
  • Avoid in uncorrected hypovolemia - ensure adequate fluid resuscitation first 2
  • Epinephrine may be less preferable than norepinephrine in cardiogenic shock after myocardial infarction due to higher incidence of refractory shock 4
  • High-dose epinephrine may be harmful in asphyxia-related shock (Class III, LOE B) 1

Epinephrine remains a critical agent in the management of refractory shock, but careful dosing, monitoring, and awareness of its metabolic effects are essential for safe and effective use.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Refractory Hypotension

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.